Clinical Trials
36 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06369259 2026-05-20
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04331041 2026-05-08
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05787561 2026-04-28
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06394804 2026-04-23
CHAMELEON
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07126158 2026-04-15
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 2 Recruiting
NCT06495125 2026-04-06
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University
Phase 2 Recruiting
NCT06072781 2026-04-02
RAMP 301
Verastem, Inc.
Phase 3 Recruiting
NCT06007924 2026-03-27
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05636514 2026-03-18
CELESTIAL-MDS
Clinical Hub for Interventional Research (CHOIR)
Phase 1 Recruiting
NCT03875820 2026-03-10
FRAME
Institute of Cancer Research, United Kingdom
Phase 1 Active not recruiting
NCT03727880 2026-02-04
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT06630260 2026-01-21
5G-RUBY
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT05074810 2026-01-12
RAMP203
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT07318324 2026-01-06
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT06682572 2025-12-17
RAMP201J
Verastem, Inc.
Phase 2 Active not recruiting
NCT05798507 2025-12-15
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
Emory University
Phase EARLY_PHASE1 Active not recruiting
NCT06194929 2025-12-03
DETERMINE
University of Utah
Phase 1/2 Recruiting
NCT06487221 2025-11-04
Avutometinib and Defactinib in Diffuse Gastric Cancer
Columbia University
Phase 2 Recruiting
NCT05512208 2025-10-22
DURAFAK
University of Oklahoma
Phase 2 Recruiting
NCT05669482 2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT04720417 2025-07-15
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated
NCT04625270 2025-01-29
RAMP 201
Verastem, Inc.
Phase 2 Active not recruiting
NCT03287271 2024-08-12
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
University of California, San Diego
Phase 1/2 Recruiting
NCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
NCT04620330 2024-01-12
RAMP202
Verastem, Inc.
Phase 2 Completed
NCT02546531 2021-07-20
Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Washington University School of Medicine
Phase 1 Completed
NCT04201145 2020-11-17
Pembrolizumab + Defactinib In Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 1 Withdrawn
NCT02943317 2019-04-30
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
Verastem, Inc.
Phase 1 Terminated
NCT02758587 2018-03-19
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
NHS Greater Glasgow and Clyde
Phase 1/2 Unknown
NCT01778803 2017-05-17
Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
Verastem, Inc.
Phase 1 Completed
NCT01951690 2017-04-13
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Verastem, Inc.
Phase 2 Completed
NCT01943292 2017-03-09
Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies
Verastem, Inc.
Phase 1 Completed
NCT01870609 2017-01-30
COMMAND
Verastem, Inc.
Phase 2 Terminated
NCT02372227 2017-01-30
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
Verastem, Inc.
Phase 1 Terminated
NCT00787033 2017-01-25
B0761001
Verastem, Inc.
Phase 1 Completed